{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:32:45Z","timestamp":1784543565518,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To assess the safety and efficacy of Obsidio\u2122 conformable embolic (CE) for embolization in the peripheral vasculature.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods<\/jats:title>\n            <jats:p>A retrospective review of the first 21 patients treated with CE was performed. Eighteen (85.7%) patients were male, and median age was 61.5\u00a0years (range, 12\u201389\u00a0years). Technical success was defined as stasis as assessed by a static contrast column for at least 5 heartbeats on post-embolization angiography. For procedures of peripheral vascular hemorrhage, clinical success was defined as hemorrhage resolution without reintervention within 30-day follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Indications for embolization were peripheral arterial hemorrhage (<jats:italic>n<\/jats:italic>\u2009=\u200913), preoperative tumor embolization (<jats:italic>n<\/jats:italic>\u2009=\u20094), preoperative embolization of renal cell carcinoma prior to cryoablation (<jats:italic>n<\/jats:italic>\u2009=\u20092), redistribution of flow prior to Yttrium-90 radioembolization to prevent nontarget radiation delivery (<jats:italic>n<\/jats:italic>\u2009=\u20091), and parastomal variceal embolization (<jats:italic>n<\/jats:italic>\u2009=\u20091). Embolization was performed via 2.4 or 2.8 French microcatheters flushed with saline prior to embolization. Most procedures (20\/21) utilized\u2009&lt;\u20091\u00a0cc of embolic, with the quantity used ranging between 0.1 and 1.4\u00a0cc. The amount of embolic injected was determined by the embolization endpoint, i.e., filling of the vessel intended for embolization. CE was used in combination with coils placed prior to CE in 4 procedures. Follow-up was a median of 57\u00a0days (range 0\u2013244\u00a0days). Complete stasis was achieved in 100% (<jats:italic>n<\/jats:italic>\u2009=\u200921\/21) of procedures. There were no post-procedure adverse events or rebleeding.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>CE resulted in reliable vessel occlusion with no cases of rebleeding or reintervention and with no procedure-related adverse events in this series.<\/jats:p>\n            <jats:p>\n              <jats:italic>Level of Evidence<\/jats:italic>: Level 4, Case Series.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00270-025-04012-y","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T23:13:51Z","timestamp":1742426031000},"page":"559-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Single Institution Experience with\u00a0a Shear-Thinning Conformable Embolic for Endovascular Embolization"],"prefix":"10.1007","volume":"48","author":[{"given":"Olivia","family":"Kola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humza","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0134-2857","authenticated-orcid":false,"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"4012_CR1","unstructured":"Boston Scientific recalls Obsidio conformable embolic for increased bowel ischemia risk when used for lower GI bleeding. U.S. Food and Drug Administration,"},{"issue":"1","key":"4012_CR2","doi-asserted-by":"publisher","first-page":"2003327","DOI":"10.1002\/advs.202003327","volume":"8","author":"H Albadawi","year":"2020","unstructured":"Albadawi H, Altun I, Hu J, et al. Nanocomposite hydrogel with tantalum microparticles for rapid endovascular hemostasis. Adv Sci (Weinh). 2020;8(1):2003327. https:\/\/doi.org\/10.1002\/advs.202003327.","journal-title":"Adv Sci (Weinh)"},{"issue":"365","key":"4012_CR3","doi-asserted-by":"publisher","first-page":"365ra156","DOI":"10.1126\/scitranslmed.aah5533","volume":"8","author":"RK Avery","year":"2016","unstructured":"Avery RK, Albadawi H, Akbari M, et al. An injectable shear-thinning biomaterial for endovascular embolization. Sci Transl Med. 2016;8(365):365ra156. https:\/\/doi.org\/10.1126\/scitranslmed.aah5533.","journal-title":"Sci Transl Med"},{"issue":"8","key":"4012_CR4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00270-017-1703-4","volume":"40","author":"DK Filippiadis","year":"2017","unstructured":"Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40(8):1141\u20136. https:\/\/doi.org\/10.1007\/s00270-017-1703-4.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"33","key":"4012_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201901071","volume":"31","author":"J Hu","year":"2019","unstructured":"Hu J, Albadawi H, Chong BW, et al. Advances in biomaterials and technologies for vascular embolization. Adv Mater. 2019;31(33): e1901071. https:\/\/doi.org\/10.1002\/adma.201901071.","journal-title":"Adv Mater"},{"issue":"7","key":"4012_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/01.rvi.0000133505.84588.8c","volume":"15","author":"JW Kish","year":"2004","unstructured":"Kish JW, Katz MD, Marx MV, Harrell DS, Hanks SE. N-butyl cyanoacrylate embolization for control of acute arterial hemorrhage. J Vasc Interv Radiol. 2004;15(7):689\u201395. https:\/\/doi.org\/10.1097\/01.rvi.0000133505.84588.8c.","journal-title":"J Vasc Interv Radiol"},{"issue":"8","key":"4012_CR7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.jvir.2024.04.024","volume":"35","author":"K Pal","year":"2024","unstructured":"Pal K, Patel M, Chen SR, et al. A single-center experience with a shear-thinning conformable embolic. J Vasc Interv Radiol. 2024;35(8):1215\u201320. https:\/\/doi.org\/10.1016\/j.jvir.2024.04.024.","journal-title":"J Vasc Interv Radiol"},{"key":"4012_CR8","unstructured":"Pullin BD (2022) Section 510(k) premarket notification. In: U.S.F.D. Administration, (ed) Office of Regulatory Affairs. Office of Regulatory Affairs, Silver Spring, MD, pp 1\u20133"},{"issue":"4","key":"4012_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.diii.2014.11.030","volume":"96","author":"M Saeed Kilani","year":"2015","unstructured":"Saeed Kilani M, Izaaryene J, Cohen F, et al. Ethylene vinyl alcohol copolymer (Onyx\u00ae) in peripheral interventional radiology: indications, advantages and limitations. Diagn Interv Imaging. 2015;96(4):319\u201326. https:\/\/doi.org\/10.1016\/j.diii.2014.11.030.","journal-title":"Diagn Interv Imaging"},{"key":"4012_CR10","doi-asserted-by":"publisher","first-page":"32145","DOI":"10.1038\/srep32145","volume":"6","author":"F Zhou","year":"2016","unstructured":"Zhou F, Chen L, An Q, et al. Novel hydrogel material as a potential embolic agent in embolization treatments. Sci Rep. 2016;6:32145. https:\/\/doi.org\/10.1038\/srep32145.","journal-title":"Sci Rep"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04012-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-025-04012-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04012-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T04:49:44Z","timestamp":1743569384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-025-04012-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["4012"],"URL":"https:\/\/doi.org\/10.1007\/s00270-025-04012-y","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Shukla is a consultant for Varian Medical Systems. Abhishek Kumar MD is a consultant for Boston Scientific. There are no other perceived conflicts of interest from the remaining authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, formal consent is not required. The protocol (Pro2023002524) for this study was approved by the Institutional Review Board at Rutgers New Jersey Medical School.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This study has obtained IRB approval from Rutgers University, and the need for informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study, consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}